Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
291.37
-1.80 (-0.61%)
At close: Jun 26, 2026, 4:00 PM EDT
291.14
-0.23 (-0.08%)
After-hours: Jun 26, 2026, 6:19 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for Alnylam Pharmaceuticals stock have an average target of 441.63, with a low estimate of 330 and a high estimate of 550. The average target predicts an increase of 51.57% from the current stock price of 291.37.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock from 29 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 15 | 14 | 14 | 15 | 14 |
| Buy | 6 | 6 | 6 | 6 | 7 | 7 |
| Hold | 8 | 7 | 8 | 8 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 28 | 28 | 28 | 30 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Buy Maintains $550 | Buy | Maintains | $550 | +88.76% | Jun 26, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 26, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $500 | Buy | Reiterates | $500 | +71.60% | Jun 25, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $370 | Hold | Maintains | $370 | +26.99% | Jun 24, 2026 |
| Needham | Needham | Buy Maintains $510 | Buy | Maintains | $510 | +75.04% | Jun 24, 2026 |
Financial Forecast
Revenue This Year
5.63B
from 3.71B
Increased by 51.48%
Revenue Next Year
7.32B
from 5.63B
Increased by 30.19%
EPS This Year
9.50
from 5.08
Increased by 87.11%
EPS Next Year
13.77
from 9.50
Increased by 44.82%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 6.1B | 9.0B | |
| Avg | 5.6B | 7.3B | |
| Low | 5.5B | 6.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 64.7% | 60.4% | |
| Avg | 51.5% | 30.2% | |
| Low | 47.1% | 20.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 13.00 | 18.21 | |
| Avg | 9.50 | 13.77 | |
| Low | 7.94 | 11.10 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 155.9% | 91.6% | |
| Avg | 87.1% | 44.8% | |
| Low | 56.3% | 16.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.